HLHaixia Li

Haixia Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haixia Li has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Haifang Wang

    Department of Laboratory Medicine, Guangdong Provincial Key Laboratory of Precision Medical Diagnostics, Guangdong Engineering and Technology Research Center for Rapid Diagnostic Biosensors, Guangdong Provincial Key Laboratory of Single-cell and Extracellular Vesicles, Nanfang Hospital, Southern Medical University

    7 shared publications
  • Ying Gong

    Department of Laboratory Medicine Guangdong Provincial Key Laboratory of Single‐cell and Extracellular Vesicles Nanfang Hospital Southern Medical University Guangzhou China

    7 shared publications
  • Jie Xiao

    Department of Laboratory Medicine, Guangdong Provincial Key Laboratory of Precision Medical Diagnostics, Guangdong Engineering and Technology Research Center for Rapid Diagnostic Biosensors, Guangdong Provincial Key Laboratory of Single-cell and Extracellular Vesicles, Nanfang Hospital, Southern Medical University

    6 shared publications
  • Lingyue Jin

    Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

    5 shared publications
  • Hongxia Wang

    Department of Laboratory Medicine, Guangdong Provincial Key Laboratory of Precision Medical Diagnostics, Guangdong Engineering and Technology Research Center for Rapid Diagnostic Biosensors, Guangdong Provincial Key Laboratory of Single-cell and Extracellular Vesicles, Nanfang Hospital, Southern Medical University

    4 shared publications
  • Lina Duan

    Department of Laboratory Medicine, Guangdong Provincial Key Laboratory of Precision Medical Diagnostics, Guangdong Engineering and Technology Research Center for Rapid Diagnostic Biosensors, Guangdong Provincial Key Laboratory of Single-cell and Extracellular Vesicles, Nanfang Hospital, Southern Medical University

    4 shared publications

Latest Publications

  • Open Access

    The landscape of cellular immune alteration in systemic lupus erythematosus

    by Jie Xiao, Lina Duan, Jia Yang, Yulu Deng, Shuyin Pang, Hongxia Wang, Xiaofeng Yin, Haifang Wang, Yurong Qiu, Xin Li, et al.

    Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multi-organ inflammation and profound immune dysregulation. Aberrant interactions among adaptive and innate immune cells—including T cells, B cells, dendritic cells, macrophages, neutrophils, and natural killer cells—disrupt immune tolerance and perpetuate chronic inflammation. This review provides a comprehensive overview of the dysfunctional cellular immune landscape in SLE, focusing on the pathogenic crosstalk among immune cell subsets and its contribution to disease progression. We highlight the imbalance of T cell subsets (Th1, Th17, Tfh, Treg), B cell hyperactivation, and impaired regulatory cell function. Furthermore, we discuss how excessive NETosis, type I interferon signaling, and impaired apoptotic clearance amplify autoantibody production and immune complex-mediated injury. Emerging evidence positions gut microbiome dysbiosis as a critical environmental driver of immune dysregulation in SLE, characterized by depletion of beneficial butyrate-producing commensals and enrichment of pro-inflammatory taxa. This dysbiosis contributes to disease pathogenesis through gut barrier dysfunction, molecular mimicry, and short-chain fatty acid deficiency. Finally, we examine potential therapeutic strategies, including immune checkpoint modulation, metabolic interventions, and novel cellular therapies, aimed at restoring immune equilibrium in SLE.


    • 20 March 2026
      • Vol. 46  (3) , 541-549

    [Streptococcus salivarius-derived extracellular vesicles exacerbate progression of lupus nephritis by activating natural killer cells].

    by Jie Xiao, Lingyue Jin, Lina Duan, Ying Gong, Haixia Li

    To investigate the regulatory effects of Streptococcus salivarius-derived extracellular vesicles (SS-EVs) on natural killer (NK) cell activation and cytotoxic function and their role in progression of systemic lupus erythematosus (SLE). Peripheral blood and fecal samples were collected from 35 SLE patients and 38 healthy individuals to assess the number and proportion of peripheral T cells, B cells, and NK cells. Fecal DNA was extracted for PCR amplification of S. salivarius DNA fragments and quantitative analysis using agarose gel electrophoresis. SS-EVs isolated by ultracentrifugation and characterized using transmission electron microscopy, nanoparticle tracking analysis, and Western blotting were co-cultured with NK cells, whose activation status and cytotoxicity were evaluated in vitro using qPCR and flow cytometry. Twenty-four MRL/lpr mice were randomized into 3 groups (n=8) for treatment with gavage of 100 μL PBS or 20 μg E. coli-EVs or SS-EVs in 100 μL PBS. Kidney pathology, immune complex deposition, and peripheral cytokine levels were assessed with HE staining, immunofluorescence staining, and ELISA. The number and proportion of peripheral NK cells were significantly reduced (PS. salivarius was markedly increased in positive correlation with SLEDAI scores (R²=0.8369) in SLE patients. In vitro studies showed that SS-EVs significantly upregulated NK cell-activating receptors and enhanced NK-mediated cytotoxicity. In MRL/lpr mice, SS-EV treatment markedly exacerbated renal inflammation, promoted C3 and IgG immune complex deposition, and significantly increased serum levels of IL-6, TNF-α, IL-8, and CCL20. S. salivarius is enriched in the gut of SLE patients and promotes NK-cell activation by releasing SS-EVs, which induce renal inflammation and immune complex deposition and contributes to SLE progression. S. salivarius and its EVs may represent novel therapeutic targets for treatment of SLE.

  • Top Cited Papers
    Open Access

    Extracellular Vesicles of Streptococcus anginosus Mediate Gastritis via Epithelial Barrier Disruption and Macrophage‐driven Inflammation

    by Ying Gong, Lina Duan, Jie Xiao, Yulu Deng, Hongxia Wang, Yajie Zhang, Xiumei Hu, Haifang Wang, Taixue An, Xin Li, et al.

    Recent studies suggest Streptococcus anginosus ( SA ) contributes to gastric disease beyond Helicobacter pylori, yet its pathogenic mechanisms remain unclear. This study demonstrates that SA ‐derived extracellular vesicles ( SA ‐EVs) accumulate in gastric tissue, enter epithelial cells, and induce acute gastritis characterized by neutrophil infiltration and elevated cytokines (TNF‐α, IL‐6, IL‐17A). Chronic exposure leads to sustained inflammation, tight junction disruption (Claudin‐18, Occludin, ZO‐1), and mucosal damage. Proteomic analysis identified TMPC and FBP62 as virulence‐associated proteins enriched in SA ‐EVs, while transcriptomics revealed activation of macrophage polarization and cytokine‐receptor pathways. Metabolomic profiling indicated dysregulated aspartate metabolism and inflammation‐related metabolic changes, alongside increased gut SA abundance. Notably, genetic deletion of Tmpc or Fbp62 significantly attenuated SA ‐EVs pathogenicity in vivo, reducing gastric inflammation, cytokine production, and macrophage infiltration. These findings establish SA ‐EVs as key mediators of non‐ H. pylori gastritis, with TMPC and FBP62 orchestrating epithelial barrier disruption, immune activation, and metabolic dysregulation, highlights their potential as therapeutic targets.


  • Open Access

    Exploring differential gene expression and biomarker potential in systemic lupus erythematosus: a retrospective study

    by Jie Xiao, Yuhong Luo, Lina Duan, Xinru Mao, Lingyue Jin, Haifang Wang, Hongxia Wang, Jie Pan, Ying Gong, Haixia Li

    Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by inflammation and immune-mediated multi-organ system damage, accompanied by clinical manifestations such as fever, hair loss, skin rash, oral ulcers, and joint pain and swelling. SLE has been reported to affect more than 3.4 million people worldwide, of which approximately 90% are women. Purpose: This study aims to identify and characterize key hub genes implicated in SLE through comprehensive bioinformatics analyses, providing a theoretical foundation for the development of more effective therapeutic strategies. Methods: Two datasets were procured from the Gene Expression Omnibus (GEO) database: GSE13887 and GSE10325. Differentially expressed genes (DEGs) were identified and subjected to functional enrichment analysis, protein-protein interaction (PPI) network construction, and receiver operating characteristic (ROC) curve analysis to evaluate potential hub genes. The top 20 significantly upregulated and downregulated DEGs, alongside the top 15 enriched Gene Ontology (GO) terms and five Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, were screened from both datasets. Quantitative real-time PCR (RT-q PCR) was utilized to validate hub gene expression in CD3 + T cells from peripheral blood samples of SLE patients. Concurrently, flow cytometry was employed to quantify inflammatory cytokines in peripheral blood samples. Results: Bioinformatics analyses identified 1,912 DEGs in GSE13887 and 52 DEGs in GSE10325, with eight DEGs common to both datasets. Functional enrichment analysis underscored critical biological processes, notably cell-mediated cytotoxicity and cell killing. PPI network and enrichment analyses highlighted seven hub genes, among which FCER1A and RGS1 demonstrated consistent expression trends across datasets and clinical samples—FCER1A was significantly downregulated, while RGS1 was upregulated in SLE patients. ROC curve analysis confirmed their strong diagnostic potential (AUC > 0.7). Principal component analysis (PCA) further highlighted distinct gene expression profiles differentiating SLE patients from healthy controls. Clinical validation via RT-q PCR and flow cytometry corroborated these findings, demonstrating decreased FCER1A expression and increased RGS1 expression in CD3 + T cells from SLE patients. Moreover, elevated plasma levels of IL-6 and TNF-α, coupled with diminished IL-10 levels, were observed in SLE patients. These findings suggest that FCER1A and RGS1 are promising biomarkers for SLE diagnosis. Conclusions: FCER1A and RGS1 are significantly associated with SLE and serve as potential biomarkers for distinguishing SLE patients from healthy individuals. Their involvement in SLE pathogenesis underscores their potential as targets for future diagnostic and therapeutic interventions.


  • Open Access

    Extracellular Vesicles Derived From Streptococcus anginosus Aggravate Lupus Nephritis by Triggering TLR2‐MyD88‐NF‐κB Signalling in NK Cells

    by Ying Gong, Lingyue Jin, Lina Duan, Jie Xiao, Yao Li, HongXia Wang, Haifang Wang, Wanying Lin, Yi Zhang, Xiufeng Gan, et al.

    Systemic lupus erythematosus (SLE) has been linked to gut microbiome dysbiosis, notably an overabundance of Streptococcus anginosus ; however, the impact of this microbial imbalance on disease pathogenesis remains unclear. Here, we investigated the contribution of S. anginosus ‐derived extracellular vesicles ( SA ‐EVs) to SLE progression, with an emphasis on lupus nephritis (LN). Fifty‐four SLE patients and 43 healthy controls (HC) were recruited. The faecal, blood and serum samples from participants were collected. SLE disease activity (SLEDA) was evaluated by the SLEDA Index (SLEDAI). Stool S. anginosus abundance was quantified by quantitative PCR, NK cell activation by flow cytometry and serum proinflammatory cytokines profile by ELISA. Lupus‐prone MRL/lpr mice were orally administered SA ‐EVs to evaluate in vivo inflammatory responses, renal NK cell activation and renal histopathological changes. S. anginosus levels were significantly elevated in SLE patients relative to HC, positively correlated with SLEDAI scores and NK cell cytotoxicity. In vitro, SA ‐EVs stimulation of patient NK cells significantly heightened proinflammatory mediator production (granzyme B, TNF‐α), increased cytotoxicity and downregulated inhibitory receptors (TIM‐3, NKG2A, TIGIT) compared to control EVs from S. Salivarius ( SS ‐EVs). Mechanistically, lipoteichoic acid (LTA) within SA ‐EVs engaged Toll‐like receptor 2 (TLR2) on NK cells, activating MyD88/NF‐κB signalling pathway. In MRL/lpr mice, SA ‐EVs treatment increased renal immune complex deposition, upregulated renal NK cell activation markers (NKp44, NKp46), and exacerbated LN pathology with greater immune cell infiltration and inflammatory cytokine levels. Furthermore, NK cell depletion with anti‐NK1.1 antibodies significantly prolonged survival in SA ‐EVs administered mice. Thus, SA ‐EVs exacerbate SLE by hyperactivating NK cells via the TLR2‐MyD88‐NF‐κB pathway, leading to amplified systemic inflammation and aggravated LN. These findings underscore the potential of targeting SA ‐EVs for therapeutic intervention in SLE.


  • Open Access

    Advances in Cellular Immune Theranostic Approaches for Glioblastoma: Current Trends and Future Directions

    by Ying Gong, Wanying Lin, Xuechun Fang, Ruyi Zhang, Min Luo, Haoran Wu, Shuai Chu, Chuangkun Li, Yiming Peng, Zhiyan Piao, et al.

    Glioblastoma is a highly malignant type of brain tumor that remains one of the most challenging cancers to treat because of its aggressive nature, genetic heterogeneity, and immunosuppressive tumor microenvironment. Despite advances in standard treatments, such as surgery, radiation, and chemotherapy, patient outcomes remain poor, driving the need for innovative therapeutic approaches. Cellular immune theranostics, which combines therapeutic and diagnostic capabilities, has emerged as a promising strategy to combat glioblastoma. The present review discusses recent advances in cellular immunotherapy, including the development and application of chimeric antigen receptor T cells, chimeric antigen receptor natural killer cells, and macrophage‐based therapies. In addition, this review highlights the potential of oncolytic viruses and personalized tumor vaccines for improving immunotherapy outcomes. The integration of advanced diagnostic tools, such as the real‐time monitoring of therapeutic responses through immunobiomarkers and imaging techniques, is emphasized as crucial for optimizing treatment strategies. However, important challenges remain, including the complexity of immune cell engineering, the difficulties of therapeutic delivery across the blood–brain barrier, and the immunosuppressive properties of the tumor microenvironment. Overcoming these challenges through innovative methodologies will be vital for improving the efficacy of cellular immune theranostics in the treatment of glioblastoma, with the ultimate goal of improving patient survival and quality of life.


  • Exploring Gut Microbiota in Systemic Lupus Erythematosus: Insights and Biomarker Discovery Potential

    by Lingyue Jin, Jie Xiao, Yuhong Luo, Lina Duan, Ying Gong, Yao Li, Haifang Wang, Yurong Qiu, Hongxia Wang, Weinan Lai, et al.

    Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease characterized by chronic inflammation and multi-organ damage, influenced by genetic, environmental, and immunological factors. Recent research highlights the significant role of gut microbiota in the pathogenesis and progression of SLE, suggesting that dysbiosis-an imbalance in the microbial community-can contribute to disease onset and severity. The gut microbiota, through its metabolites, interacts with the host's immune system, influencing immune responses and maintaining intestinal barrier integrity. These interactions have positioned the gut microbiota as a potential source of diagnostic biomarkers and therapeutic targets for SLE. This review delves into the mechanisms by which gut microbiota influences SLE, exploring how alterations in microbial composition and function can trigger autoimmune responses. We also examine the potential of gut microbiota-derived metabolites as biomarkers for early diagnosis and disease progression monitoring. Additionally, the therapeutic implications of modulating gut microbiota through dietary interventions, probiotics, prebiotics, and other microbiota-targeted therapies are discussed as promising strategies for managing SLE. The findings suggest that a deeper understanding of the gut microbiota’s role in SLE could lead to more personalized and effective treatments, potentially transforming the approach to managing this chronic autoimmune condition. Future research should focus on elucidating the precise mechanisms of gut microbiota interaction with the immune system and its impact on SLE, as well as validating gut microbiota-based biomarkers and therapies in clinical settings.


  • Exosomes in Autoimmune Diseases: A Review of Mechanisms and Diagnostic Applications

    by Lina Duan, Wanying Lin, Yi Zhang, Lingyue Jin, Jie Xiao, Haifang Wang, Shuyin Pang, Hongxia Wang, Dehua Sun, Ying Gong, et al.

    Exosomes, small extracellular vesicles secreted by various cell types, have emerged as key players in the pathophysiology of autoimmune diseases. These vesicles serve as mediators of intercellular communication, facilitating the transfer of bioactive molecules such as proteins, lipids, and nucleotide. In autoimmune diseases, exosomes have been implicated in modulating immune responses, oxidative stress, autophagy, gut microbes, and the cell cycle, contributing to disease initiation, progression, and immune dysregulation. Recent advancements in exosome isolation techniques and their molecular characterization have paved the way for exploring their clinical potential as biomarkers and therapeutic targets. This review focuses on the mechanisms by which exosomes influence autoimmune disease development and their potential clinical applications, particularly in diagnosis. The role of exosomes in autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), type 1 diabetes mellitus (T1DM), inflammatory bowel disease (IBD), and Sjögren’s syndrome (SS), is discussed in relation to their involvements in antigen presentation, T-cell activation, and the induction of inflammatory pathways. Additionally, exosome-based biomarkers offer promising non-invasive diagnostic tools for early diagnostic, disease monitoring, and therapeutic response assessment. However, challenges such as standardization of exosome isolation protocols and validation of their clinical significance remain. This review highlights the potential of exosomes as both diagnostic biomarkers and therapeutic targets in autoimmune diseases, emphasizing the need for further research to overcome current limitations and fully harness their clinical value.


  • Open Access

    The prognosis and immune repertoire characteristics of HBsAg and anti-HBs double positive chronic hepatitis B patients

    by Huijun Liang, Haifang Wang, Minfeng Liang, Xiaobin Zhang, Meifen Dai, Haixia Li, Xin Li, Xiaofeng Yin, Xinyao Liu, Jiaqi Yao, et al.

    Coexistence of hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs) has been observed in some chronic hepatitis B (CHB) patients (DP patients), but the clinical outcomes and comprehensive characterization of immune micro-environmental changes for this specific population remain inconclusive. In this study, we retrospectively analyze the prognosis of 305 patients in Foshan City, Guangdong Province, China, and also investigated the molecular immunology changes in HBsAg and anti-HBs double positive CHB patients (DP group), CHB patients who had recovered from IFN-ɑ treatment (RP group), and healthy controls (HC group) using T cell receptor (TCR) and B cell receptor (BCR) immune repertoire sequencing. Our findings revealed that 22.30% of DP patients were diagnosed with severe liver disease. Immune repertoire sequencing revealed significant skewing in the diversities of T cell receptor β-chain (TRB) and immunoglobulin heavy chain (IGH) in the DP group compared to the RP group. Unique V(D)J gene combinations, such as IGHV1-18/IGHD3-22/IGHJ5, IGHV1-8/IGHD6-13/IGHJ3, and IGHV1-8/IGHD6-19/IGHJ3, as well as TRBV12-3/TRBD1/TRBJ1-5 and TRBV11-2/TRBD2/TRBJ2-1, exhibited distinct utilization patterns in the DP group. Moreover, the top ten most utilized amino acid motifs in the complementarity determining region 3 (CDR3) of TRB in the DP group showed significant differences from those in the RP group. Notably, motifs such as “xxxYDSSGYx” and “AREx” in the IGH CDR3s were selectively prevalent in the DP group. These findings are expected to provide evidence supporting the poor clinical prognosis of DP patients and offer new insights into the distinct immune micro-environmental changes of this group.


  • Open Access

    Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells

    by Haifang Wang, Chen Fu, Jun Du, Hongsheng Wang, Rui He, Xiaofeng Yin, Haixia Li, Xin Li, Hongxia Wang, Kui Li, et al.

    Background: Drug resistance is a major obstacle to treating cancers because it desensitizes cancer cells to chemotherapy. Recently, attention has been focused on changes in the tumor immune landscape after the acquisition of drug resistance. Programmed death-ligand-1 (PD-L1) is an immune suppressor that inhibits T cell-based immunity. Evidence has shown that acquired chemoresistance is associated with increased PD-L1 expression in cancer cells. However, the underlying mechanism is still largely unknown. Methods: PD-L1 expression in three drug-resistant A549/CDDP, MCF7/ADR and HepG2/ADR cell lines was detected by qRT-PCR, western blotting and flow cytometry, and a T cell proliferation assay was performed to test its functional significance. Then, the potential roles of JNK/c-Jun, histone H3 acetylation, histone deacetylase 3 (HDAC3) and the E3 ligase COP1 in the PD-L1 increase were explored through ChIP assays and gain- and loss-of-function gene studies. Furthermore, murine xenograft tumor models were used to verify the role of JNK/c-Jun and HDAC3 in PD-L1 expression in A549/CDDP cells in vivo. Finally, the correlations of PD-L1, c-Jun and HDAC3 expression in clinical cisplatin-sensitive and cisplatin-resistant non-small cell lung cancer (NSCLC) tissues were analyzed by immunohistochemistry and Pearson’s correlation coefficient. Results: PD-L1 expression was significantly increased in A549/CDDP, MCF7/ADR and HepG2/ADR cells and was attributed mainly to enhanced JNK/c-Jun signaling activation. Mechanistically, decreased COP1 increased c-Jun accumulation, which subsequently inhibited HDAC3 expression and thereby enhanced histone H3 acetylation of the PD-L1 promoter. Furthermore, PD-L1 expression could be inhibited by JNK/c-Jun inhibition or HDAC3 overexpression in vivo, which could largely reverse inhibited CD3+ T cell proliferation in vitro. PD-L1 expression was significantly increased in the cisplatin-resistant clinical NSCLC samples and positively correlated with c-Jun expression but negatively correlated with HDAC3 expression. Conclusions: Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis was crucial for the PD-L1 increase in drug-resistant cancer cells. Our study reveals a novel regulatory network for the PD-L1 increase in drug-resistant cancer cells and that combined PD-L1-targeting strategies could improve T cell-based immunity in drug-resistant cancers.